Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
Sauman Singh-PhulgendaPrabin DahalRoland NguBrittany J MaguireAlice HawryszkiewyczSumayyah RashanMatthew BrackChristine M HalleuxFabiana AlvesKasia StepniewskaPiero L OlliaroPhilippe J GuerinPublished in: PLoS neglected tropical diseases (2021)
Mortality within the first 30 days of VL treatment initiation was a rarely reported event in clinical trials with an overall estimated rate of 0.068 deaths per 1,000 person-days at risk, though it varied across regions and patient populations. These estimates may serve as a benchmark for future trials against which mortality data from prospective and pharmacovigilance studies can be compared. The methodological limitations exposed by our review support the need to assemble individual patient data (IPD) to conduct robust IPD meta-analyses and generate stronger evidence from existing trials to support treatment guidelines and guide future research.